TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34324100
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone intravenously (IV) preoperatively
Study: 34324100
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone from a nebulizer mask preoperatively
Study: 34143199
Drug: Sonic activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonic activation of desensitizing agent (DA) containing 5% potassium nitrate and 2% sodium fluoride, activated for 30 seconds per tooth.
Study: 34143199
Drug: Desensitizing agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desensitizing agent (DA) without sonic activation, applied for 10 minutes.
Study: 34143199
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (SA and noSA)
Study: 36445624
Drug: Genotype-guided (GG)
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided (GG) escalation of P2Y12 inhibitor therapy post PCI
Study: 34510193
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid (FA) supplementation (5 mg/d for 12 weeks)
Study: 35841243
Drug: Adenosine Triphosphate
Normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine Triphosphate (ATP) infusion
Study: 36327309
Drug: Rectal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal progesterone suppository
Study: 34887528
Drug: Intranasal 24IU
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 24IU oxytocin
Study: 34016346
Drug: Ice slurry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice slurry (4 g⋅kg ‐1 body weight, 0.5 °C)
Study: 35779189
Drug: NX210 (0.4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NX210 (0.4, 1.25, 2.5, 5, and 10 mg/kg)
Study: 35422611
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion (1.5 mg/kg bolus before anesthesia induction, followed by 2.0 mg/kg/h continuous infusion until end of surgery)
Study: 32863142
Drug: Chloride-rich intravenous
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloride-rich intravenous fluid (0.9% saline)
Study: 36579554
Drug: US-guided corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided corticosteroid injections combined with a personalized rehabilitation program (Group A; n: 19)
Study: 36579554
Drug: US-guided corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided corticosteroid injections alone (Group B; n: 18)
Study: 35107855
Drug: Ayahuasca (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (average 1.58 mg/ml DMT) in healthy volunteers
Study: 35107855
Drug: Ayahuasca (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (average 0.680 mg/ml DMT) in volunteers with SAD
Study: 32455019
Drug: Daily ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ingestion of 60 mg iron and 0.4 mg folic acid
Study: 32779607
Drug: Silane coupling
Normalized name: silane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silane coupling agent application (SL)
Study: 32779607
Drug: No surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No surface treatment (C)
Study: 33856973
Drug: Mindfulness-based schema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based schema (MBS) therapy
Study: 36060196
Drug: 1WS (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1WS (once-weekly support by specialized therapists)
Study: 36060196
Drug: 1W/1BD-S (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1W/1BD-S (once-weekly support supplemented with one-business-day response to emails)
Study: 36060196
Drug: 1WC (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1WC (once-weekly support by therapists in community clinics)
Study: 36328912
Drug: Active distraction
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active distraction (tablet)
Study: 35485835
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Social Anxiety (CBT-SA)
Study: 32835417
Drug: Zoledronate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoledronate treatment
Study: 32739319
Drug: XP‐RT (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP‐RT (adjuvant concurrent chemo‐radiotherapy)
Study: 32739319
Drug: XP (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP (chemotherapy alone)
Study: 32396700
Drug: Oral PrEP
Normalized name: Iron bivalent, oral preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PrEP initiation
Study: 34282831
Drug: Needle-assisted injections
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-assisted injections
Study: 34282831
Drug: Cannula-assisted injections
Normalized name: CANNULA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannula-assisted injections
Study: 32438301
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (200 mL of inert solution)
Study: 34853395
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin D3
Study: 35460725
Drug: 20% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% albumin (0.5-1.0 g/kg over 3 hours)
Study: 35460725
Drug: Plasmalyte (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmalyte (30 ml/kg over 3 hours)
Study: 33399254
Drug: Abemaciclib added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib added to adjuvant endocrine therapy
Study: 33399254
Drug: Adjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endocrine therapy alone
Study: 33481463
Drug: Telehealth exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth exercise intervention (functional circuit exercise training via videoconferencing, 3 times weekly for 12 weeks)
Study: 33853731
Drug: Full-dose almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose almonds (73±5 g/d)
Study: 33853731
Drug: Half-dose almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose almonds (38±3 g/d) plus half-dose muffins
Study: 32494210
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (10 sessions over 3 weeks)
Study: 35080256
Drug: Daclatasvir 60
Normalized name: daclatasvir 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 60 mg plus alfosbuvir 400 mg daily (Cohort A)
Study: 35080256
Drug: Daclatasvir 60
Normalized name: daclatasvir 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 60 mg plus alfosbuvir 600 mg daily (Cohort B)
Study: 35080256
Drug: Daclatasvir 60
Normalized name: daclatasvir 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 60 mg plus alfosbuvir 800 mg daily (Cohort C)
Study: 34871153
Drug: Ciclesonide (CIC)
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide (CIC) 40, 80, or 160 µg/day
Study: 34871153
Drug: Ciclesonide (CIC)
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide (CIC) 160 µg/day
Study: 34871153
Drug: Ciclesonide (CIC)
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide (CIC) 80 or 160 µg/day
Study: 34265236
Drug: Ivermectin 12
Normalized name: Ivermectin 12 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 12 mg on day 1 and 2 post enrolment
Study: 35553398
Drug: Insufficient maternal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insufficient maternal vitamin D (< 50 nmol/l) during gestational weeks 18-22
Study: 35553398
Drug: Sufficient maternal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufficient maternal vitamin D (≥ 50 nmol/l) during gestational weeks 18-22
Study: 34554201
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (fluorouracil dosing every 2 weeks)
Study: 33865361
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (50,000 IU/week) plus Magnesium (6 mg/kg/day)
Study: 36209731
Drug: Monterizine (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monterizine (combination of montelukast and levocetirizine)
Study: 33762421
Drug: IV metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV metoclopramide 20 mg + diphenhydramine 25 mg (M + D)
Study: 33369462
Drug: Oral mefenamic
Normalized name: meclofenamate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mefenamic acid (500 mg) 30 minutes before procedure
Study: 33369462
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical tablet) 30 minutes before operation
Study: 35687793
Drug: OC‐01 VNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC‐01 VNS 0.03 mg
Study: 35687793
Drug: CsA 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA 0.05% ophthalmic emulsion
Study: 33628014
Drug: 0.5 μg·kg‐1·h‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg·kg‐1·h‐1 dexmedetomidine combined with butorphanol (3 μg·kg‐1·h‐1)
Study: 33628014
Drug: 0.05 μg·kg‐1·h‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 μg·kg‐1·h‐1 dexmedetomidine combined with butorphanol (3 μg·kg‐1·h‐1)
Study: 33628014
Drug: 0.08 μg·kg‐1·h‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08 μg·kg‐1·h‐1 dexmedetomidine combined with butorphanol (3 μg·kg‐1·h‐1)
Study: 33628014
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride combined with butorphanol (3 μg·kg‐1·h‐1)
Study: 35442393
Drug: Digital health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital health intervention with gamification (virtual teams, points, levels for daily step goal achievement)
Study: 35442393
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving daily feedback on goal attainment
Study: 32986770
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (IVL)
Study: 32986770
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous lidocaine (Control)
Study: 35384422
Drug: Fluvoxamine 100
Normalized name: fluvoxamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 100 mg twice daily for 10 days
Study: 34348011
Drug: Relaxation techniques
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation techniques (diaphragmatic breathing, progressive muscular relaxation, autogenic training, guided imagery) for 8 weeks, with weekly sessions and daily practice (2 times/day) using a compact disk.
Study: 34348011
Drug: Relaxation techniques
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation techniques (treatment group).
Study: 33326929
Drug: Musical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Musical stimulation (15 minutes once daily for 7 days using an MP3 player and headphones)
Study: 33326929
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (silent headphones for 15 minutes once daily for 7 days)
Study: 33043347
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (ornidazole + periodontal tissue regeneration)
Study: 32960748
Drug: New glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New glucose-lowering drug
Study: 35248549
Drug: GB001 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB001 40 mg
Study: 35248549
Drug: GB001 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB001 60 mg
Study: 32172441
Drug: Internet-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based therapy for depressive symptoms
Study: 35281318
Drug: 0.5 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg/mL dexmedetomidine combined with 0.075% ropivacaine
Study: 35281318
Drug: 0 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 μg/mL dexmedetomidine combined with 0.075% ropivacaine
Study: 35281318
Drug: 0.1 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 μg/mL dexmedetomidine combined with 0.075% ropivacaine
Study: 35281318
Drug: 0.2 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg/mL dexmedetomidine combined with 0.075% ropivacaine
Study: 35281318
Drug: 0.3 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 μg/mL dexmedetomidine combined with 0.075% ropivacaine
Study: 35281318
Drug: 0.4 μg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 μg/mL dexmedetomidine combined with 0.075% ropivacaine
Study: 32624244
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide insert (FAi) 0.2 μg/day
Study: 32620212
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab for 4 injections followed by nivolumab alone (arms 1B and 4B)
Study: 32620212
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitor (sunitinib or pazopanib at investigator's choice) (arms 2C and 3C)
Study: 33123838
Drug: OPT‐A (integrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPT‐A (integrated family‐based outpatient treatment)
Study: 33017651
Drug: Airways therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Airways therapy for OSA
Study: 36385314
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 6 mg kg−1
Study: 34448448
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies in primary school students
Study: 34448448
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies in secondary school students
Study: 34448448
Drug: IgG antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG antibodies in household members
Study: 35780195
Drug: Ventilatory settings
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ventilatory settings (median tidal volume 7 mL/PBW, PEEP 7 cmH20, plateau pressure 20 cmH20, driving pressure 12 cmH20, mechanical power 16.2 J/min, ventilatory ratio 1.27, respiratory rate 17 breaths/min)
Study: 32281410
Drug: Antenatal education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal education (two 2-hr sessions twice a week for 4 weeks)
Study: 32091467
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound therapy (CON, n = 16)
Study: 33177393
Drug: 1% benvitimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% benvitimod cream
Study: 33177393
Drug: 1% benvitimod
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% benvitimod cream (retreatment)
Study: 39033766
Drug: Cream vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream vehicle
Study: 34218046
Drug: Subcutaneous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous hydrocortisone
Study: 36360666
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide injection, periodontal scaling, and oral hygiene instruction (experimental group)
Study: 36360666
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide injection (control group)
Study: 35681097
Drug: Lactoferrin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin 100 mg/day for 3 months
Study: 35681097
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate 6 mg/kg/day for 3 months
Study: 33736484
Drug: Standard weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard weekly coaching sessions (Control)
Study: 32434498
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of autologous adipose tissue
Study: 33880752
Drug: Lactiplantibacillus plantarum
Normalized name: Lactiplantibacillus plantarum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactiplantibacillus plantarum 299v (Lp299v, 1010 colony forming units), 4.2 mg iron, 12 mg ascorbic acid and 30 µg folic acid (Lp)
Study: 36104105
Drug: Music therapy-led
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy-led breathing exercises for 6 weeks
Study: 34173669
Drug: RCTs involving
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCTs involving any type of systemic therapy
Study: 34173669
Drug: PIs having
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PIs having accepted payment(s) from the manufacturer of the drug utilized in their RCT
Study: 32101663
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus neoadjuvant chemotherapy (200 mg every 3 weeks)
Study: 32101663
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus neoadjuvant chemotherapy
Study: 34470186
Drug: MNT administered
Normalized name: MNTX
DrugBank: Methylnaltrexone (DB06800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MNT administered monthly (Group A)
Study: 34470186
Drug: MNT administered
Normalized name: MNTX
DrugBank: Methylnaltrexone (DB06800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MNT administered every 3 months (Group B)
Study: 34470186
Drug: No access
Approvals — FDA: no, EMA: no, PMDA: no
Description: No access to nutritional therapy (Group C)
Study: 36282220
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 20 mL 0.375% bupivacaine
Study: 36282220
Drug: Thoracal paravertebral
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracal paravertebral block (TPVB) with 20 mL 0.375% bupivacaine
Study: 35957925
Drug: Serum glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum glucose > 120 mg/dL
Study: 35957925
Drug: Serum cortisol
Normalized name: Serum cortisol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum cortisol > 10 μg/dL
Study: 35957925
Drug: Leptin ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin ≥ 15 ng/mL
Study: 35957925
Drug: GDNF ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDNF ≥ 20 pg/mL
Study: 33840474
Drug: Oxygen delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen delivery strategy (maintaining an oxygen delivery index value >300 mL/min/m2 through pump flow adjustments)
Study: 32861603
Drug: Taurine 3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine 3,000 mg/day for 8 weeks
Study: 34748214
Drug: Conversational agent
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conversational agent (dialogic reading)
Study: 34563585
Drug: Luseogliflozin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luseogliflozin 2.5 mg/day
Study: 35102226
Drug: Desogestrel (DSG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel (DSG 150 µg/d, n=50)
Study: 35102226
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA 10 mg/d, n=54)
Study: 32346706
Drug: Continuous curvilinear
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous curvilinear buccal‐cervical incision
Study: 32346706
Drug: Conventional cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cervical T shaped incision combined with a buccal incision
Study: 34528981
Drug: LGG fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGG fermented milk (150 mL containing 108 CFU mL‐1 LGG)
Study: 35822565
Drug: medication withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: medication withdrawal
Study: 35881121
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid (30 mg/kg bolus, 16 mg/kg/h maintenance, 2 mg/kg prime)
Study: 35881121
Drug: Low-dose tranexamic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tranexamic acid (10 mg/kg bolus, 2 mg/kg/h maintenance, 1 mg/kg prime)
Study: 35881121
Drug: High-dose tranexamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tranexamic acid
Study: 32279172
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy (AVT)
Study: 35610712
Drug: CHW-led intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHW-led intervention (monthly household visits for 1 year)